Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.32 - $0.67 $11,280 - $23,617
-35,250 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$0.72 - $2.93 $7,814 - $31,799
10,853 Added 44.48%
35,250 $25,000
Q4 2021

Feb 11, 2022

SELL
$2.26 - $3.34 $28,760 - $42,504
-12,726 Reduced 34.28%
24,397 $55,000
Q3 2021

Nov 12, 2021

SELL
$2.35 - $3.88 $3,024 - $4,993
-1,287 Reduced 3.35%
37,123 $107,000
Q1 2021

May 12, 2021

BUY
$2.92 - $5.06 $112,157 - $194,354
38,410 New
38,410 $129,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $329M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.